Zydus Buys Stake In Sterling Biotech – Will API Segment Restructuring Accelerate?
PE Interest Has Been Growing
Executive Summary
Does Zydus’ 50% stake acquisition in Sterling Biotech reflect a broader move of formulations companies to secure API supplies or acceleration of API segment restructuring begun by a couple of private equity (PE) funds?